Abstract 4637: Olaparib in patients with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study


1Cancer Treatment Centers of America, Chicago, IL; 2American Society of Clinical Oncology, Alexandria, VA; 3Duke University Medical Center, Durham, NC; 4University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; 5University of Michigan Rogel Cancer Center, Ann Arbor, MI; 6Sutter Health Roseville Cancer Center, Roseville, CA; 7The Angeles Clinic and Research Institute, Los Angeles, CA; 8Fox Chase Cancer Center, Philadelphia, PA; 9University of Alabama Birmingham Medical Center, Birmingham, AL; 10Emory University Winship Cancer Institute, Atlanta GA; 11Cancer Research Consortium of West Michigan, Grand Rapids, MI; 12University of Nebraska Medical Center, Omaha, NE; 13Swedish Cancer Institute, Edmonds, WA; 14Levine Cancer Institute, Shelby, NC

Olaparib has anti-tumor activity in heavily pre-treated patients with pancreatic cancer with germline or somatic BRCA1/2 inactivating mutations.

Future Direction: Findings consistent with recent studies of O in this pt population. Further study warranted.

Table 1: Efficacy Outcomes (N=28)1

<table>
<thead>
<tr>
<th>DC rate, % (90% CI)</th>
<th>31 (18, 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR rate, % (95% CI)</td>
<td>7 (0, 24)</td>
</tr>
<tr>
<td>1 year OS, % (95% CI)</td>
<td>48.2 (26.0, 67.3)</td>
</tr>
</tbody>
</table>

12 enrolled pts were not evaluable and are excluded from efficacy analyses

Funding supported by AstraZeneca. The authors would like to acknowledge the patients who participated in this cohort as well as Josefa Briceno, MD, clinical lead of AstraZeneca, a TAPUR supporting pharmaceutical company.

Contact: TAPURPublications@asco.org

Olaparib has anti-tumor activity in heavily pre-treated patients with pancreatic cancer with germline or somatic BRCA1/2 inactivating mutations.

Future Direction: Findings consistent with recent studies of O in this pt population. Further study warranted.